RCUS
HealthcareArcus Biosciences, Inc.
$21.77
$-1.52 (-6.53%)
Jan 5, 2026
Price History (1Y)
Analysis
Arcus Biosciences, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $2.69 billion and 627 employees. The company's financial health reveals significant challenges. It reported a net income loss of -$341 million on revenue of $240 million over the trailing twelve months (TTM), resulting in operating margins of -546.2% and profit margins of -142.1%. This is accompanied by negative EBITDA of -$365 million, free cash flow of -$139 million, and a debt-to-equity ratio of 30.27. The company's valuation metrics highlight its volatility, with a forward P/E ratio of -5.63 and an EV/EBITDA ratio of -4.97. The price to book ratio is 5.35, while the price to sales ratio stands at 11.22. The stock has traded between $6.50 and $26.40 over the past year, with a beta of 0.78 indicating relatively low volatility compared to the market as a whole.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Visit website →Key Statistics
- Market Cap
- $2.69B
- P/E Ratio
- N/A
- 52-Week High
- $26.40
- 52-Week Low
- $6.50
- Avg Volume
- 1.87M
- Beta
- 0.78
Company Info
- Industry
- Biotechnology
- Exchange
- NYQ
- Country
- United States
- Employees
- 627